Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.9900 (-1.8%) ($5.9100 - $6.1900) on Thu. Jul. 11, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.25% (three month average) | RSI | 63 | Latest Price | $5.9900(-1.8%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | ADMS advances 1.8% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IGOV(10%) LQD(6%) VCIT(6%) SHY(5%) JETS(4%) | Factors Impacting ADMS price | ADMS will decline at least -1.625% in a week (0% probabilities). INDA(-8%) BNDX(-7%) XLE(-6%) USO(-6%) URA(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.625% (StdDev 3.25%) | Hourly BBV | 0 () | Intraday Trend | -1.5% | | | |
|
5 Day Moving Average | $5.96(0.5%) | 10 Day Moving Average | $5.98(0.17%) | 20 Day Moving Average | $5.65(6.02%) | To recent high | -9.7% | To recent low | 18.6% | Market Cap | $169m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |